
Pharmaceutical companies should consider what is required for QIDP designation and whether they can use it to extend the protection afforded to their innovative products.
Jennifer H. Roscetti, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Ms. Roscetti counsels clients in all aspects of intellectual property law with a focus in the pharmaceutical and chemical arts. She has extensive litigation experience representing pharmaceutical patent holders in U.S. district court and appellate proceedings involving the Hatch-Waxman Act governing the approval of pharmaceutical products. Ms. Roscetti also advises clients on the interplay of U.S. patent law and FDA approval for marketing pharmaceutical products.

Pharmaceutical companies should consider what is required for QIDP designation and whether they can use it to extend the protection afforded to their innovative products.

Published: May 7th 2018 | Updated: